The 2 Nutrition Label Details Strength Coaches Watch When They Want to Drop Fat Fast
Don't get us wrong, though, grabbing a packaged snack every now and then isn't a dealbreaker. The key is knowing what to look for. For starters, we suggest trying to find options made with real ingredients, a list that isn't pushing double digits, and ideally something that actually expires. If it can survive a nuclear winter, maybe skip it. Also, avoid labels claiming to be 'healthy' or 'low-fat,' as these are generally just marketing tactics.
In a recent video with Steven Bartlett, Certified Strength and Conditioning Specialist and ATHLEAN-X founder Jeff Cavaliere also laid out the two things he always looks for if he's trying to drop fat fast.
"I always look for sugar and fat," he says. "So [with] dietary fat, there are nine calories per gram of fat versus four calories per gram of protein or carbohydrate. They're a much more calorie-dense food."While Cavaliere points out that fat isn't inherently bad (some fat is actually essential for overall health), it is calorie-dense. That means the more fat something contains, the higher its calorie count tends to be.
"When you have fats on your plate in any way, shape, or form, calorically that dish is going to increase pretty quickly," he says. "So you have to be mindful of them if you if you want to lose weight and achieve a hypocaloric state. To get there, you're going to have to take in fewer calories than you're burning, that's why I would look at fat content."
Sugar, on the other hand, is something Cavaliere tries to avoid altogether. While he isn't against the ingredient itself, he points out that our bodies don't actually need it, and eating too much of it regularly can do more harm than good.
"Sugar is just one of those things that our bodies do not need and tends to be too inviting to the point where people have a hard time stopping eating [it]," he says. "So I think that's one of the fastest ways to get yourself on track is to try to minimize the sugar content in the food."
To keep hunger and cravings in check, Cavaliere tries to stick to high-protein foods. That might sound tough if you're always on the go, but having simple options like boiled eggs, protein shakes, or clean beef or turkey jerky on hand can make a big difference.
The 2 Nutrition Label Details Strength Coaches Watch When They Want to Drop Fat Fast first appeared on Men's Journal on Jul 16, 2025
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Associated Press
5 minutes ago
- Associated Press
Scientist.com Expands Tumor Model Finder with XenoSTART's Highly Relevant, Patient-Derived Tumor Models
SAN DIEGO--(BUSINESS WIRE)--Jul 23, 2025-- the leading R&D procurement orchestration platform for the life sciences, today announced a major expansion of its Tumor Model Finder (TMF) following a strategic partnership with XenoSTART, a global leader in patient-derived xenograft (PDX) model development and testing. The addition of hundreds of unique and high-demand XenoSTART models pushes the TMF past a milestone of 10,000 searchable oncology models, giving cancer researchers unprecedented access to diverse and clinically relevant tools. 'Pharma discovery teams often face critical delays accessing translational research partners with deeply characterized PDX models that accurately reflect real-world patient disease complexity,' said Michael J. Wick, PhD, Chief Scientific Officer at XenoSTART. 'By joining the marketplace, XenoSTART eliminates this significant barrier, providing immediate access to our highly relevant, patient-derived tumor models that are directly linked to our global clinical network. This integration empowers drug developers to confidently accelerate therapeutic decision-making and precisely guide their translational strategies—ultimately speeding effective cancer treatments to patients.' Tumor Model Finder is a centralized, AI-powered platform that aggregates and standardizes tumor model data from 20+ leading CROs. It allows researchers to search, compare, and source PDX, CDX, organoid, and cell line models—spanning 17 cancer types—through a single workflow. The platform also includes drug response profiles, genomic alterations (e.g., KRAS, BRAF mutations), and RNA seq-based gene expression data to support informed model selection and study design. 'XenoSTART's contribution significantly boosts the depth and quality of our TMF offerings,' said Javier Pineda, PhD, Director of Preclinical AI at 'Researchers can now find models with richer data and greater relevance to their specific cancer studies.' This collaboration also highlights the translational impact of START's global research ecosystem. With patient-derived tissue samples sourced from START's expansive oncology trial network, XenoSTART's models provide critical continuity between preclinical evaluation and clinical trial execution—helping pharmaceutical companies make faster, more confident decisions in oncology drug development. To learn more or schedule a demo of the Tumor Model Finder, email [email protected]. About is the life-science industry's premier AI-powered marketplace and procurement-orchestration platform. Founded in 2007 and headquartered in Solana Beach, California, the company simplifies every stage of drug discovery and development by unifying supplier search, competitive bidding, contracting, compliance and analytics in a single, secure workspace. More than 20 of the world's top 30 pharma companies, 100+ biotech organizations and the US National Institutes of Health rely on to access a vetted network of 6,000+ specialized providers, shorten cycle times and reduce costs while meeting the highest ethical and regulatory standards. Visit to discover how we accelerate science. About XenoSTART Founded in 2007, XenoSTART is a translational research organization dedicated to advancing oncology drug development through clinically relevant preclinical cancer models. The XenoSTART Patient-Derived Xenograft (XPDX) platform features more than 2,800 models across a broad range of tumor types and disease stages sourced from patients treated at START's domestic and international cancer centers. Models are deeply characterized using histologic analysis, DNA/RNA sequencing, and in vivo drug sensitivity testing, and are clinically annotated with the donor patient's treatment history and clinical outcome. By bridging real-world tumor biology with rigorous preclinical science, XenoSTART enables pharmaceutical partners to make smarter, faster decisions from bench to bedside. Learn more about XenoSTART at View source version on CONTACT: Sean Preci +1 877-644-3044 [email protected] XenoSTART Lauren Panco 609-216-4920 KEYWORD: EUROPE UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: OTHER HEALTH RESEARCH PHARMACEUTICAL ONCOLOGY TECHNOLOGY ARTIFICIAL INTELLIGENCE GENETICS HEALTH TECHNOLOGY SCIENCE BIOTECHNOLOGY OTHER SCIENCE HEALTH SOURCE: Copyright Business Wire 2025. PUB: 07/23/2025 07:55 AM/DISC: 07/23/2025 07:55 AM

Associated Press
6 minutes ago
- Associated Press
Avel eCare Appoints Martainn Lenhardt as Chief Financial Officer to Lead Financial Strategy Amid Rapid Growth and Innovation
SIOUX FALLS, SD / ACCESS Newswire / July 23, 2025 / Avel eCare, a leading provider of telemedicine services in the United States, today announced the appointment of Martainn Lenhardt as Chief Financial Officer (CFO). Lenhardt brings over 20 years of healthcare finance experience to the role, where he will oversee Avel's financial strategy, operations, and performance during a pivotal era of innovation and nationwide expansion. Lenhardt joins Avel eCare following his tenure as VP of Finance at Lyric and senior leadership roles at Change Healthcare, where he managed a $480 million business unit and was instrumental in driving growth and improving margins. He is widely recognized for his expertise in strategic growth, mergers and acquisitions, and optimizing global operations. His ability to turn complexity into opportunity and build agile, purpose-driven teams will be instrumental in advancing Avel's mission. 'Avel eCare is transforming how healthcare is delivered across the country,' said Lenhardt. 'It's an honor to join this team and help scale a model that brings high-quality, virtual care to every corner of the nation.' This appointment comes at a time of unprecedented momentum for Avel eCare. In the past two years alone, Avel has launched new service lines, secured exclusive partnerships with organizations like Amwell and Cibolo Health, and expanded services to more than 46 states. The company continues to innovate with in-ambulance telehealth, ICU solutions, and programs that support EMS, law enforcement, and correctional health, making care more accessible, cost-effective, and consistent, especially in rural and underserved areas. The new CFO joins an accomplished executive team committed to advancing healthcare access and outcomes across the country. Avel's leadership includes: About Avel eCare Avel eCare is a national leader in technology-enabled clinical services delivered through telemedicine, offering provider-to-provider virtual care solutions that expand clinical capacity and improve outcomes across the healthcare industry. With more than 30 years of innovation, Avel's board-certified clinicians partner with hospitals, clinics, long-term care facilities, schools, EMS agencies, and correctional health systems nationwide to bring high-quality care to patients when and where it's needed most. Learn more at: Media Contact: Jessica Gaikowski Avel eCare [email protected] SOURCE: Avel eCare press release


Washington Post
6 minutes ago
- Washington Post
The world should strive to end PEPFAR
Last week, the President's Emergency Plan for AIDS Relief narrowly escaped a devastating $400 million budget cut thanks to Republican Sens. Susan Collins (Maine) and Lisa Murkowski (Alaska), who voted alongside their Democratic colleagues to protect the program. That was a relief: Since its creation under President George W. Bush in 2003, the anti-HIV/AIDS program has saved an estimated 26 million lives and enabled 7.8 million babies to be born HIV-free.